Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.